Don’t miss the latest developments in business and finance.

Zydus Lifesciences receives USFDA approval for Isosorbide Mononitrate ER Tablets

Image
Last Updated : Feb 16 2024 | 2:50 PM IST

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg (USRLD: Imdur Extended-Release Tablets).

Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease).

The product will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg had annual sales of USD 47 mn in the United States (IQVIA Dec. Nov. 2023).

Powered by Capital Market - Live News

Also Read

First Published: Feb 16 2024 | 2:31 PM IST

Next Story